Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Adagene
Adagene
(ADAG)
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
*Currency in USD
Company Revenue
Quarterly
Quarterly
Annual
Annual
Projections
*Annual sales USD (in millions)
Mock data
Subscribe for the real data
Revenue by Drug
Marketed Drugs
No data
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Tiragolumab
colorectal neoplasms
,
triple negative breast neoplasms
,
squamous cell carcinoma of head and neck
,
breast neoplasms
,
small cell carcinoma
,
uterine cervical neoplasms
,
urologic neoplasms
,
urinary bladder neoplasms
,
transitional cell carcinoma
,
pancreatic neoplasms
,
stomach neoplasms
,
rectal neoplasms
,
melanoma
,
non-hodgkin lymphoma
,
lymphoma
,
follicular lymphoma
,
b-cell lymphoma
,
carcinoma
,
squamous cell carcinoma
,
renal cell carcinoma
,
recurrence
,
microsatellite instability
,
non-small-cell lung carcinoma
,
small cell lung carcinoma
,
liver neoplasms
,
neoplasms
,
esophageal neoplasms
,
hepatocellular carcinoma
,
esophageal squamous cell carcinoma
Gilvetmab
healthy volunteers/patients
,
neoplasms
,
melanoma
TOBEMSTOMIG
liver neoplasms
,
esophageal squamous cell carcinoma
,
renal cell carcinoma
,
non-small-cell lung carcinoma
,
breast neoplasms
,
hepatocellular carcinoma
ADG206
neoplasms
ADG-106
breast neoplasms
,
neoplasms
,
triple negative breast neoplasms
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use